There is no translation available. Traduzione non disponibile.

  • D3 Validation © 2016 IIT 5023
  • D3 Validation © 2016 IIT 5022

Our lab's mission is to discover and validate transformative therapeutic targets, with the ultimate goal of creating safe and effective new drugs for pain, inflammation, neurodegeneration and psychiatric disorders.

Recent examples of our work include:

  • N-acylethanolamine acid amidase (NAAA). NAAA is a cysteine amidase that catalyzes the degradation of two endogenous analgesic and anti-inflammatory lipids, palmitoylethanolamide and oleoylethanolamide. NAAA is mainly expressed in cells of the immune system. Our group has discovered the first classes of potent and selective NAAA inhibitors and demonstrated that these agents cause profound analgesic and anti-inflammatory effects in animal models. These compounds were out-licensed to a biopharmaceutical company in the US, and one of them is undergoing preclinical development. We continue to investigate the roles of NAAA and explore its value as a therapeutic target.
  • Peripherally restricted fatty acid amide hydrolase (FAAH) inhibitors. FAAH is a serine amidase that degrades the endogenous cannabinoid anandamide. We discovered the first systemically active inhibitor for this enzyme in 2003 and, more recently, we identified a new group of FAAH inhibitors that do not enter the brain and spinal cord. These peripherally restricted agents produce marked analgesia in animal models, without any of the side effects of current painkillers. The lead compound in this class is scheduled to start preclinical development in 2016.
  • Acid ceramidase (AC). AC is a cysteine amidase that degrades the sphingolipid messenger ceramide, into sphingosine and fatty acid. Ceramide plays a key role in the control of cellular senescence and programmed cell death. For this reason, AC inhibitors offer hope in the treatment of disease states characterized by dysregulated cell proliferation. We created the first classes of potent and selective AC inhibitors, including systemically active compounds that were recently out-licensed to a biopharmaceutical company in the US.
  • Multi-target FAAH and cyclooxygenase (Cox) inhibitors. We have shown that simultaneous inhibition of FAAH and Cox activities with designed multi-target agents, provides an effective and safe strategy to treat inflammatory bowel disease, a non-resolving inflammatory conditions that is currently undertreated. 

Activities

  • Medicinal Chemistry: We design and synthesize novel chemical probes for targets of interest and, when appropriate, develop those probes into preclinical and clinical candidates. Two of our molecules have entered preclinical development and one is undergoing lead optimization.
  • Analytical and bioanalytical chemistry: We use sophisticated analytical tools to support our medicinal chemistry work (e.g., determination of compound solubility, stability and pharmacokinetics). We also utilize ‘omics’ approaches (proteomics and lipidomics) to discover new biological mechanisms and identify potential targets for drug discovery.
  • Pharmacology: We characterize our compounds and validate target proteins using functional in vitro analyses and animal models of disease.

Collaborations

We have active scientific collaborations with academic labs and pharmaceutical companies. Some examples include

  • Istituto Neurologico "C. Mondino” (Pavia, Italy): FAAH inhibition as a therapeutic target for migraine treatment: studies in animal models and preliminary evaluation in humans (funded by the Italian Ministero della Salute)
  • Angelini (Pomezia, Italy):  Studies on novel GSK3b inhibitors for psychiatric disorders.
  • Naicons (Milan, Italy): Characterization of a novel class of bacteria-derived peptides as analgesics.
  • Lysosomal Therapeutics (Boston, USA):  Studies on novel AC inhibitors.